Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
NCT02621944Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Nov 2016
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of melatonin in hypoxic-ischemic encephalopathy (HIE) (3 arms), sponsored by University of Florida. Primary endpoints: Maximum Tolerated Dose at day 3, Bayley Scales of Infant and Toddler Development, Third Edition and 2 more. Started Nov 2016; status: recruiting.
02
Drugs
melatonin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT02621944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621944.